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Abstract 
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, but the overall prognosis 
remains disappointing especially in the advanced-stage patients. Aberration expression of Aurora kinases 
is tumorigenic and thus it has attracted interests as therapeutic targets in cancer treatment. Here, we 
investigated the proteomic response of HCC Hep3B cells to danusertib (Danu), a pan-Aurora kinase 
inhibitor, and then validated the proteomic results based on stable-isotope labeling by amino acids in cell 
culture (SILAC). The proteomic data identified that Danu modulated the expression of 542 protein 
molecules (279 up-regulated; 260 down-regulated; 3 stable). Ingenuity pathway analysis (IPA) and KEGG 
pathway analysis identified 107 and 24 signaling pathways were regulated by Danu, respectively. IPA 
analysis showed cellular growth and proliferation, and cell death and survival were among the top five 
molecular and cellular functions regulated by Danu. The verification experiments showed that Danu 
inhibited the proliferation of Hep3B cells with a 24-hr IC50 value of 22.03 µM. Danu treatment also 
arrested Hep3B cells in G2/M phase via regulating the expression of key cell cycle regulators and induced 
apoptosis via mitochondria-dependent pathway in a dose-dependent manner. Besides, Danu induced a 
marked autophagy, and inhibition of autophagy enhanced the anticancer effects of Danu, indicating a 
cyto-protective role of Danu-induced autophagy. Our proteomic data and Western blotting assays 
showed the PI3K/Akt/mTOR signaling pathway was involved in the inducing effect of Danu on apoptosis 
and autophagy. Collectively, our findings have demonstrated that the Aurora kinases inhibition with 
danusertib results in global proteomic response and exerts anticancer effects in Hep3B cells involving 
regulation of cell cycle, apoptosis and autophagy and associated signaling pathways. 
Key words: Hepatocellular carcinoma; Aurora kinases; danusertib; cell cycle; apoptosis; autophagy, quantitative 
proteomics. 
Introduction 
Liver cancer is a major malignancy burden and 
global public health problem [1, 2]. According to the 
GLOBOCAN 2012 by World Health Organization, 
there were 782,500 new cases of liver cancer 
(accounting for 5.6% of all cancers) and 745,500 liver 
cancer-caused deaths (9.1% of total) globally in 2012 
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[3]. This malignancy is the 5th most common cancer in 
men (554,000 cases) and the 9th in women (228,000 
cases). According to the National Cancer Institute, 
40,710 patients would be diagnosed with liver cancer 
in the United States (US) in 2017 and 28,920 would die 
of this disease. Liver cancer is the 10th most common 
cancer and the 5th most common cause of cancer 
death among men; incidence of liver cancer has 
tripled in the US since 1980 [4]. In China, liver cancer 
is the 4th most common cancer after lung, stomach, 
and esophagus cancer; it is the 3rd leading cause of 
cancer-related death after lung and stomach cancer 
[5]. The estimated new liver cancer cases were 466,100 
(343,700 men and 122,300 women) and estimated 
deaths due to liver cancer were 422,100 (310,600 men 
and 111,500 women) in China in 2015 [5]. The overall 
5-year survival rate for liver cancer patients is ∼18%; 
for liver cancer patients who are diagnosed at an early 
stage, the 5-year survival rate is 31%; but the 5-year 
survival rate drops down to only 3% if the cancer has 
metastasized in liver cancer patients in the US [6]. The 
main risks of liver cancer in the US are liver cirrhosis 
and nonalcoholic fatty liver disease; whereas hepatitis 
B and C infection and aflatoxin exposure are the major 
risk factors for liver cancer in China [7, 8]. 
Hepatocellular carcinoma (HCC) accounts for 85-90% 
of all liver cancers, which can be divided into two 
subclasses: proliferative and non-proliferative, each 
depending on distinct pathways [9, 10]. Mutations in 
the TERT promoter, p53, ARID1A, CDKN2A, 
CTNNB1, AXIN1, and CCND1 are very common in 
HCC [7, 8, 10]. Critical molecular events in HCC 
pathogenesis include activated WNT signaling 
pathway due to mutations in CTNNB1 and AXIN1, 
alterations in p53 and the PI3K/Akt/mTOR 
pathways, aberrant cell cycle regulation and 
angiogenesis, and epigenetic changes [10]. The main 
treatment modalities for HCC include surgery, 
radiofrequency ablation, percutaneous ethanol 
injection, radiation therapy, chemoembolization and 
radioembolization, targeted therapy, and 
immunotherapy [7, 11-15]. To date, only sorafenib 
(Nexavar, co-developed by Bayer and Onyx 
Pharmaceuticals Inc.) and regorafenib (Stivarga, 
developed by Bayer HealthCare Pharmaceuticals 
Inc.), two targeted multi-kinase inhibitors, have been 
approved by the Food and Drug Administration 
(FDA) to treat HCC patients [16]. Sorafenib has been 
used as a first-line therapy in patients with advanced 
stage HCC for a decade and has set the stage for 
personalized targeted therapy [15, 17]. Its role has 
ranged from monotherapy to neoadjuvant and 
adjuvant treatment with surgical resection, liver 
transplantation and chemoembolization. Regorafenib 
inhibits multiple kinases involved in tumor 
proliferation and angiogenesis, causing a survival 
benefit as a second-line therapy in HCC when 
sorafenib fails [16, 18]. However, tumor resistance and 
adverse effects are two major limiting factors for the 
targeted therapy of liver cancer [19]; the overall 
prognosis remains dismal in patients with late-stage 
liver cancer. Therefore, seeking new therapeutic 
agents for advanced HCC is still mandatory. 
Aurora kinases, consisting of three family 
members, Aurora kinase A, B and C, are one of the 
serine-threonine kinases and involved in multiple 
mitotic events [20]. In recent years, aberrant 
expression of these kinases has been proved to be 
tumorigenic in many types of cancer, including HCC 
[21, 22]. Targeting Aurora kinase has become an 
attractive target for new anticancer treatments and 
many Aurora kinase inhibitors have been developed 
and evaluated in preclinical to clinical studies [23-26]. 
Recently, we have found that the Aurora kinase A 
inhibitor alisertib induces autophagy and cell cycle 
arrest and enhances chemosensitivity in HepG2 cells 
[27]. Furthermore, we have reported that danusertib 
(Danu) [28], a small molecule pan-Aurora kinase 
inhibitor, kills ovarian, gastric and breast cancer and 
leukemia cells via induction of apoptosis and 
autophagy involving AURKB/p70S6K/RPL15 and 
PI3K/Akt/mTOR signaling pathways [29-32]. Several 
Phase I and II studies have shown that Danu has 
limited efficacy but is well tolerated by cancer patients 
[33-37]. However, the evidence on its effects on HCC, 
especially the effect on the global proteomic response, 
is still limited. 
Mass spectrometry-based proteomics is 
increasingly employed in a quantitative way to 
investigate protein expression changes in biological 
samples, often based on labeling of samples with 
stable isotopes that are introduced chemically or 
metabolically. Stable-isotope labeling by amino acids 
in cell culture (SILAC) is a powerful and increasingly 
popular approach for quantitative proteomics studies 
in vitro and in vivo [38-41]. In the SILAC study, two 
cell populations are cultured in the presence of heavy 
or light amino acids (typically lysine and/or 
arginine), one of them is subject to a perturbation (e.g. 
drug exposure), and then both are combined, 
processed, and analyzed. Incorporation of the "heavy" 
amino acid occurs through cell growth, protein 
synthesis, and turnover. SILAC allows "light" and 
"heavy" proteomes to be distinguished by mass 
spectrometry while avoiding any chemical 
derivatization and associated purification. SILAC can 
be applied to systemically evaluate global protein 
profile, investigate and identify the target networks of 
drugs, drug toxicity, and new biomarkers for diseases 
[40, 42, 43]. The purpose of this study was to evaluate 
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the proteomic responses and validated the molecular 
targets of Danu in Hep3B cells using a combination of 
proteomic and cell-based approaches, with a focus on 
cell cycle progression, apoptosis, and autophagy.  
Materials and methods 
Chemicals and Reagents 
Danu was purchased from Selleckchem Inc 
(Houston, TX, USA). Dulbecco’s phosphate buffered 
saline (PBS), fetal bovine serum (FBS), thiazolyl blue 
tetrazolium bromide (MTT), RNase A, propidium 
iodide, 13C6 L-lysine, 13C6 15N4 L-arginine and 
L-arginine, and chloroquine (CQ) were purchased 
from Sigma-Aldrich Inc. (St Louis, MO, USA). 
Dulbecco’s Modified Eagle’s Medium (DMEM) was 
obtained from Corning Cellgro Inc (Herndon, VA, 
USA). Phenol red-free culture medium and 
4,6-diamidino-2-phenylindole were bought from 
Invitrogen Inc. (Carlsbad, CA, USA). The Cyto-ID® 
autophagy detection kit was obtained from Enzo Life 
Sciences Inc. (Farmingdale, NY, USA). The Pierce 
bicinchoninic acid (BCA) protein assay kit, skim milk, 
and Western blot substrate were purchased from 
Thermo Scientific Inc. (Waltham, MA, USA). 
Polyvinylidene difluoride (PVDF) membrane was 
purchased from EMD Millipore Inc. (Bedford, MA, 
USA). Primary antibodies against human cyclin B1, 
p-cyclin B1 at Ser 133, cell division cycle protein 2 
homologue (CDC2), p-CDC2 at Tyr15, p-CDC25C at 
Ser216, cytochrome c, Bcl-2-like protein 
4/Bcl-2-associated X protein (Bax), B-cell lymphoma- 
extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved 
caspase 9, cleaved caspase 3, p53 up-regulated 
modulator of apoptosis (PUMA), cleaved poly-ADP- 
ribose polymerase (cleaved-PARP), Akt, p-Akt at 
Ser473, mammalian target of rapamycin (mTOR), 
p-mTOR at Ser2448, PI3K, p-PI3K/p85 at Tyr458, 
beclin1, SQSTM1/p62, microtubule-associated 
protein 1A/1B-light chain 3 (LC3)-I, and LC3-II were 
all purchased from Cell Signaling Technology Inc. 
(Beverly, MA, USA). The antibody against human 
β-actin was obtained from Santa Cruz Biotechnology 
Inc. (Santa Cruz, CA, USA).  
Cell line, cell culture and Danu treatment 
Hep3B cells were obtained from the American 
Type Culture Collection (Manassas, VA, USA) and 
cultured in DMEM medium supplemented with 10% 
heat-inactivated FBS and 1% penicillin/streptomycin. 
The cells were maintained in a 5% CO2/95% 
air-humidified incubator at 37°C. Danu was dissolved 
in DMSO with a stock concentration of 100 mM and 
the stock solution was stored at -20°C. Danu was 
freshly diluted to the predetermined concentrations 
with culture medium. The control cells received the 
vehicle only. Hep3B cells were treated with Danu at 
0.01, 0.1, and 0.5 µM for 24 hr, and then subject to flow 
cytometric analysis and confocal microscopic 
examination. The protein samples were subject to 
Western blotting assay.  
Quantitative proteomic study using SILAC 
Quantitative proteomic experiments were 
performed using a SILAC-based approach as 
described previously [29, 44]. Briefly, Hep3B cells 
were cultured in DMEM-F12 medium (for SILAC) 
with (heavy) or without (light) stable isotope labeled 
amino acids (13C6 L-lysine and 13C6 15N4 L-arginine) 
and 10% dialyzed FBS. Hep3B cells cultured in heavy 
medium were treated with 0.5 µM Danu for 24 hr after 
six cell doubling times. After treatment with Danu, 
Hep3B cells were harvested and lysed with hot lysis 
buffer (100 mM Tris base, 4% sodium dodecyl sulfate 
[SDS], and 100 mM dithiothreitol), and protein 
concentration was determined using ionic detergent 
compatibility reagent. Subsequently, equal amounts 
of heavy and light protein samples were combined to 
reach a total volume of 30–60 µL containing 300–600 
µg protein. The combined protein sample was 
digested using a filter-aided sample prep (FASP™) 
protein digestion kit and desalted using a C18 
solid-phase extraction column. The peptide mixtures 
(5 µL) were subject to the hybrid linear ion trap (LTQ 
Orbitrap XL™, Thermo Fisher Scientific Inc.). Liquid 
chromatography-tandem mass spectrometry was 
performed using a 10 cm long, 75 µm (inner diameter) 
reversed-phase column packed with 5 µm diameter 
C18 material having a pore size of 300 Å (New 
Objective Inc., Woburn, MA, USA) with a gradient 
mobile phase of 2–40% acetonitrile in 0.1% formic acid 
at 200 µL per min for 125 min. The Orbitrap full mass 
spectrometry scanning was performed at a mass 
(m/z) resolving power of 60,000, with positive 
polarity in profile mode (M + H+). Peptide SILAC 
ratio was calculated using MaxQuant version 1.2.0.13. 
The SILAC ratio was determined by averaging all 
peptide SILAC ratios from peptides identified of the 
same protein. The protein IDs were identified using 
Scaffold 4.3.2 from Proteome Software Inc. (Portland, 
OR, USA). 
Pathway analysis using IPA and DAVID 
The pathway was analyzed using ingenuity 
pathway analysis (IPA) from QIAGEN (Redwood 
City, CA, USA) and the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) [45]. 
DAVID was also used to provide biological functional 
interpretation of the potential targets of Danu. 
Enrichment scores and Fisher’s exact test P-values 
(and corresponding false discovery rate [FDR]) were 
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calculated to identify which functional related gene 
groups were significantly enriched in the target list. 
These significant enriched gene groups could explain 
the mechanism of action of Danu systematically.  
Cell viability assay 
The MTT assay was performed to examine 
Hep3B cells viability. Hep3B cells were seeded in 
96-well culture plates at a density of 8,000 cells per 
well. After incubation for 24 hr, the cells were treated 
with Danu at different concentrations ranging from 
0.01 to 50 μM for 24 hr. In the autophagy inhibition 
experiments, the cells were coincubated with Danu 
and CQ for 24 hr. Absorbance at the 450 nm 
wavelength was measured with a Synergy H4 Hybrid 
microplate reader (BioTek Inc., Winooski, VT, USA). 
IC50 values were determined using the relative 
viability over Danu concentration curve by GraphPad 
Prism 6.0 (GraphPad Software Inc., La Jolla, CA, 
USA). 
Cell cycle distribution analysis 
The effect of Danu on cell cycle distribution of 
Hep3B cells was examined using flow cytometry as 
previously described [46]. Propidium iodide is used 
as a DNA stain in cell cycle analysis. A total number 
of 1×104 cells were subject to cell cycle analysis using a 
flow cytometer (Becton Dickinson Immunocytometry 
Systems, San Jose, CA, USA). 
Quantification of cellular apoptosis  
The effect of Danu on the apoptosis of Hep3B 
cells was quantitated using the annexin V: PE 
apoptosis detection kit (BD Biosciences Inc.) 
according to the manufacturer’s instruction. In brief, 
the cells were collected after Danu treatment at 
different concentrations over 24 hr, or evaluated for 
different time intervals, and resuspended and 
incubated in 100 μL 1 × binding buffer containing 5 µL 
annexin V:PE and 5 μL 7-amino-actinomycin D 
(7-AAD) in the dark at room temperature for 15 min. 
The number of apoptotic cells was analyzed by flow 
cytometer (Becton Dickinson Immunocytometry 
Systems, San Jose, CA, USA) within 1 hr.  
Quantification of cellular autophagy 
To determine the effect of Danu on autophagy in 
Hep3B cells, the intracellular autophagy level was 
examined using the Cyto-ID® autophagy detection kit 
(No. ENZ-51031-K200) according to the 
manufacturer’s instructions. In brief, cells were 
collected after Danu treatment at different conditions 
and resuspended in 250 µL of assay buffer containing 
5% FBS. Following with the addition of 250 µL of the 
diluted Cyto-ID® Green stain solution, cells were 
incubated at room temperature in the dark for 20 min, 
then cells were collected and washed with 1 × assay 
buffer. The percentage of autophagy cells was 
analyzed using the green (FL1) channel of a flow 
cytometer (Becton Dickinson Immunocytometry 
Systems, San Jose, CA, USA). 
Confocal fluorescence microscopic 
examination 
The cellular autophagy level was further 
detected using confocal fluorescence microscopy. The 
cells were also dyed with Cyto-ID® green detection 
and Hoechst 33342 nuclear stain reagent contained in 
the Cyto-ID® autophagy detection kit (No. 
ENZ-51031-K200) according to the manufacturer’s 
instructions. The cells were examined using a Leica 
TCS SP2 laser scanning confocal microscopy (Leica 
Microsystems, Wetzlar, Germany) using a standard 
FITC filter set for imaging the autophagic signal at 
wavelengths of 405/488 nm.  
Western blotting analysis 
The expression levels of various cellular proteins 
were determined using Western blotting assays. 
Protein samples were collected in the RIPA buffer (50 
mmol HEPES at pH 7.5, 150 mmol NaCl, 10% glycerol, 
1.5 mmol MgCl2, 1% Triton-X 100, 1 mmol EDTA at 
pH 8.0, 10 mmol sodium pyrophosphate, 10 mmol 
sodium fluoride) containing the protease inhibitor 
and phosphatase inhibitor cocktails, and centrifuged 
at 3,000 × g for 10 min at 4oC. Protein concentrations 
were determined using the BCA assay and 20 µg 
samples were resolved by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
sample loading buffer and electrophoresed on 7−12% 
SDS-PAGE mini-gel after thermal denaturation at 
95oC for 5 min. Proteins were transferred onto PVDF 
membrane at 400 mA for 2 h at 4oC. Membranes were 
probed with indicated primary antibody overnight at 
4oC and then blotted with respective secondary 
anti-mouse or anti-rabbit antibody. Visualization was 
performed using Bio-Rad ChemiDocTM XRS system 
(Hercules, CA, USA) with enhanced chemilumi-
nescence substrate. The blots were analyzed using 
ImageLab 3.0 (Hercules) and protein level was 
normalized to the matching densitometric value of 
β-actin as internal control. 
Statistical analysis 
Data are presented as the mean ± standard 
deviation (SD). Comparisons of multiple groups were 
evaluated by one-way analysis of variance followed 
(ANOVA) by Tukey’s multiple comparison 
procedure. A value of P<0.05 was considered 
statistically different. Assays were performed at least 
three times independently. 
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Results 
Proteomic response to Danu treatment in 
Hep3B cells 
First, we performed a SILAC-based proteomic 
study to quantitatively determine the general 
proteomic response to 0.5µM Danu treatment in 
Hep3B cells. Danu treatment increased the expression 
level of 279 protein molecules, but decreased the 
expression level of 260 protein molecules (Table S1). 
Subsequently, these proteins were subject to IPA and 
DAVID analysis. The IPA results showed that 109 
signaling pathways were regulated by Danu in Hep3B 
cells (Table S2, Figure S1). KEGG pathway analysis 
showed that 24 signaling pathways were modulated 
by Danu (Table 2). As shown in Table S3, 18 
functional clusters were identified to be significantly 
enriched (enrichment score > 5). The top five 
molecular and cellular functions regulated by Danu in 
Hep3B cells (IPA analysis) were cellular growth and 
proliferation, protein synthesis, cell death and 
survival, RNA post-transcriptional modification, and 
gene expression (Table 1). Then we focused on 
analyzing the effect of Danu on cell cycle distribution, 
apoptosis, and autophagy, which are related to 
cellular growth and proliferation, cell death, and 
survival.  
 
Table 1. Top five molecular and cellular functions regulated by 
Danu in Hep3B cells. 
Names P-value range Molecules 
Cellular growth and proliferation 4.19×10-4 - 7.19×10-33 263 
Protein synthesis 1.69×10-4 - 3.29×10-30 138 
Cell death and survival 4.60×10-4 - 8.60×10-30 258 
RNA post-transcriptional modification 3.34×10-4 - 8.30×10-22 54 
Gene expression 5.47×10-4 - 4.95×10-20 153 
 
Danu inhibits the proliferation of Hep3B cells 
We first verified the effect of Danu on the 
proliferation of Hep3B cells using MTT assay. A 
concentration-dependent inhibitory effect of Danu on 
the growth of Hep3B cells was observed (Figure 1). 
Danu regulates the cell cycle distribution of 
Hep3B cells 
Compared to the control cells (100%), the 
percentage of the viability of Hep3B cells decreased to 
91.7, 84.1, 77.9, 70.9, 64.8, 52.4, and 43.1%, 
respectively, when cells were treated with Danu at 
0.01, 0.1, 0.5, 1, 5, 25, and 50 µM for 24 hr. The IC50 
value was 22.03 µM. The results show that Danu 
inhibits the proliferation of Hep3B cells. 
As shown in Table S2 and Table 2, both IPA 
(Pathway No. 30) and DAVID (Pathway No. 23) 
analysis have identified the effect of Danu on the cell 
cycle distribution. We next used flow cytometry to 
validate this effect. The data showed that Danu 
treatment induced cell cycle arrest at G2/M phase in a 
concentration-dependent manner. Compared to the 
basal level (15.4%), the percentage of Hep3B cells 
arrested at G2/M phase ascended to 57.3% (P<0.001, 
Figure 2A) and 53.3% (P<0.001, Figure 2A), when cells 
were treated with Danu at 0.1 and 0.5 μM for 24 hr, 
respectively. On the contrary, there was a marked 
reduction in the number of cells at G1 phase when 
treated with 0.1 and 0.5 μM Danu for 24 hr.  
 
Table 2: The KEGG pathways by the DAVID database for the 
target list of Danu in Hep3B cells 
 Pathway Gene count P-Value Fold Enrichment 
1  Spliceosome 26 5.24×10-10 4.34 
2  Aminoacyl-tRNA biosynthesis 12 1.93×10-6 6.15 
3  Ribosome 17 2.28×10-6 4.11 
4  Pathogenic Escherichia coli infection 11 2.86×10-4 4.06 
5  Glycolysis / Gluconeogenesis 11 4.40×10-4 3.85 
6  Antigen processing and presentation 12 1.68×10-3 3.04 
7  Methane metabolism 4 1.89×10-3 14.01 
8  Fatty acid metabolism 8 2.39×10-3 4.20 
9  Cysteine and methionine metabolism 7 4.67×10-3 4.33 
10  Pentose phosphate pathway 6 5.58×10-3 5.04 
11  Proteasome 8 6.10×10-3 3.58 
12  Citrate cycle (TCA cycle) 6 1.41×10-2 4.07 
13  Oocyte meiosis 12 1.44×10-2 2.29 
14  Prion diseases 6 2.32×10-2 3.60 
15  Tight junction 13 2.42×10-2 2.04 
16  Glutathione metabolism 7 2.94×10-2 2.94 
17  Pyruvate metabolism 6 3.89×10-2 3.15 
18  Tryptophan metabolism 6 3.89×10-2 3.15 
19  Systemic lupus erythematosus 10 4.39×10-2 2.12 
20  Regulation of actin cytoskeleton 17 4.77×10-2 1.66 
21  Fatty acid elongation in mitochondria 3 5.18×10-2 7.88 
22  Focal adhesion 16 5.2×10-2 1.67 
23  Cell cycle 11 7.13×10-2 1.85 
24  Base excision repair 5 8.16×10-2 3.00 
Abbreviations: KEGG, Kyoto encyclopedia of genes and genomes; Danu, 
danusertib 
 
 
Figure 1. Cytotoxicity of Danu towards Hep3B cells determined by the MTT assay. 
 
Danu alters the expression of key cell cycle 
regulators in Hep3B cells 
We next used Western blotting assay to further 
validate the effect of Danu on the cell cycle 
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distribution. Our results demonstrated treatment with 
Danu at 0.5 μM resulted in a 45.8% (P<0.01, Figure 2B) 
decrease in the total level of CDC2 and a 55.3% 
(P<0.05, Figure 2B) increase in the phosphorylation (at 
Tyr15) level. There was a remarkable decrease (57%, 
P<0.01, Figure 2B) in the level of p-cyclin B1 at Ser133, 
while there was a marked increase (30.2%, P<0.01, 
Figure 2B) in the total level of cyclin B1 when cells 
were treated with 0.5 μM Danu. We further detected 
the level of p-CDC25C (Ser216), a kinase responsible 
for the de-phosphorylation of CDC2 (Tyr15). 
Treatment with Danu at 0.5 μM up-regulated the 
expression level of p-CDC25C (Ser216) by 77.4% 
(P<0.05, Figure 2B). These findings indicate Danu 
treatment results in an inactivation of CDC2/CDK1- 
cyclin B1 complex, which leads to cell arrest at G2/M 
phase. 
Danu induces apoptosis in Hep3B cells 
Both IPA (Table S2, Pathway No. 63 and No. 66) 
and DAVID (Table S3, Cluster No. 18) analysis have 
revealed the effect of Danu on the apoptosis of Hep3B 
cells. We next used flow cytometry and Western 
blotting assay to validate the pro-apoptotic effect of 
Danu. As shown in Figure 3A, compared to the 
control cells, treatment with Danu at 0.5 μM resulted 
in a 2.16-fold increase in the overall apoptotic rate 
(P<0.01, Figure 3A). The Western blotting assays 
showed that Danu treatment at 0.5 μM significantly 
up-regulated the level of cleaved PARP 1.9-fold, a 
marker of cellular apoptosis.  
Since DAVID (Table S3, Cluster No. 18) analysis 
have demonstrated a number of protein molecules 
involved in the regulation of apoptosis, we further 
examined the expression levels of pro-apoptosis and 
anti-apoptosis proteins. As shown in Figure 3B, 
compared to the control cells, there were a 33.5% and 
52.1% reduction, respectively, in the level of Bcl-xl 
and Bcl-2 (P<0.01, Figure 3B), while there was a 
1.9-fold elevation in the level of Bax (P<0.01, Figure 
3B), when Hep3B cells were treated with 0.5 μM 
Danu. Mitochondrial dysfunction (Table 1, Pathway 
No. 42) following remarkable increase in the ratio of 
Bax/Bcl-2 leads to the release of cytochrome c. 
Indeed, we observed that Danu treatment at 0.1 and 
0.5 μM increased the level of cytosolic cytochrome c 
by 88.2% and 85.6%, respectively (P<0.01, Figure 3B). 
Subsequently, we observed a remarkable increase in 
the level of cleaved caspases 9 (1.62-fold) and 3 
(1.69-fold). Additionally, Danu also up-regulated the 
negative regulator of Bcl-2 family, PUMA, in Hep3B 
cells. Treatment of cells with Danu at 0.5 μM resulted 
in 2.4-fold increase in the level of PUMA compared to 
the control cells (P<0.001, Figure 3B). Taken together, 
 
Figure 2. Danu treatment arrested Hep3B cells in G2/M phase via regulating the expression of key cell cycle regulators. Hep3B cells were treated with Danu at 0.01, 0.1, and 0.5 
µM for 24 hr, and then subject to flow cytometric analysis. The protein samples were subject to Western blotting assay. Representative flow cytometric plots of cell cycle 
distribution (A) and blots of p-CDC25C (Ser216), p-CDC2/CDK1 (Tyr15), CDC2/CDK1, p-cyclin B1 (Ser133), and cyclin B1 (B). Bar graphs show the percentage of Hep3B cells 
in G1, S, and G2/M phases and the relative level of the above proteins. β-Actin was used as the internal control. Data are the mean ± SD of three independent experiments. 
*P<0.05, **P<0.001 and ***P<0.001 by one-way ANOVA. 
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the results indicate that Danu exhibits via activation 
of mitochondria-dependent pathway. 
Danu induces autophagy in Hep3B cells 
As shown in Table S2 and Table 2, a number of 
pathways were regulated by Danu treatment based on 
the IPA and DAVID analysis. Of note, near one third 
(IPA analysis) or half (DAVID analysis) of them were 
involved in the nutrition and energy metabolism. 
Functional cluster No. 18 is also in regard to nutrition 
and energy metabolic process (Table S3). These 
findings indicate the regulatory role of Danu in 
intracellular hemostasis.  
We speculated that Danu treatment would exert 
a significant effect on the autophagy in Hep3B cells. In 
order to validate the pro- or anti-autophagic effect of 
Danu, flow cytometry, confocal microscopic 
examination, and Western blotting assay were 
performed.  
As shown in Figure 4, treatment with Danu 
markedly increased the level of autophagy in a 
concentration-dependent manner. Our flow 
cytometric data showed treatment with Danu at 0.1 
and 0.5 µM for 24 hr resulted in a 3.1- and 3.4-fold 
increase in the percentage of autophagic cells 
compared to the control cells (basal level = 8.3%) 
(P<0.001, Figure 4A). The confocal microscopic 
examination showed that autophagic level was 
increased 1.9- and 2.7-fold when Hep3B cells were 
treated with Danu at 0.1 and 0.5 µM for 24 hr, 
respectively (P<0.001, Figure 4B).  
As shown in Figure 4C, the result of LC3 
turnover assay was positive, since the ratio of 
LC3-II/LC3-I was elevated by 41% when cells were 
treated with 0.5 µM Danu (P<0.05, Figure 4C). The 
expression level of another autophagic marker, beclin 
1, was up-regulated (P<0.05, Figure 4C). SQSTM1/ 
p62 accumulates when autophagy is inhibited, and 
decreased level can be observed when autophagy is 
induced. Treatment of Hep3B cells with Danu at 0.5 
μM resulted in a 32% decrease in the level of 
SQSTM1/p62 (P<0.05, Figure 4C). In aggregate, these 
results demonstrate the inducing effect of Danu on 
autophagy in Hep3B cells. 
Danu regulates the PI3K/Akt/mTOR signaling 
pathway in Hep3B cells 
Accumulating evidence suggest that the 
PI3K/Akt/mTOR signaling pathway is involved in 
the regulation of both apoptosis and autophagy [47]. 
Our data have demonstrated that Danu induced 
apoptosis and autophagy. As shown in Table 1, 
mTOR signaling, one of the top five IPA canonical 
pathways, along with PI3K/Akt signaling (Pathway 
No. 29), have been regulated by Danu treatment. So 
we next used Western blotting assay to validate the 
 
Figure 3. Danu treatment induced apoptosis via mitochondria-dependent pathway. Hep3B cells were treated with Danu at 0.01, 0.1, and 0.5 µM for 24 hr, and then subject to 
flow cytometric analysis. The protein samples were subject to Western blotting assay. Representative flow cytometric plots of cell cycle distribution (A) and blots of cytochrome 
c, Bax, Bcl-xl, Bcl-2, cleaved caspase 9, cleaved caspase 3, PUMA, and cleaved PARP (B). Bar graphs show the percentage of autophagic Hep3B cells and the relative level of the 
above proteins. β-Actin was used as the internal control. Data are the mean ± SD of three independent experiments. *P<0.05, **P<0.001 and ***P<0.001 by one-way ANOVA. 
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regulatory effect of Danu on this well-known 
pathway. Danu treatment at 0.1 and 0.5 µM markedly 
inhibited the phosphorylation of PI3K at Tyr199 in 
Hep3B cells, but did not impact the expression of total 
PI3K, leading to a 22.1% and 39.3% decrease in the 
ratio of p-PI3K/PI3K, respectively (P<0.05 or 0.01, 
Figure 5). Danu inactivated PI3K resulted in an 
inhibition of the phosphorylation of Akt at Ser473. 
Consequently, the ratio of p-Akt/Akt decreased 
64.6% when cells were exposed to 0.5 µM Danu for 24 
hr (P<0.01, Figure 5). Inhibition of mTOR was 
detected following the inactivation of PI3K/Akt 
pathway in these HCC cells. Danu inhibited the 
phosphorylation of mTOR and the ratio of 
p-mTOR/mTOR was decreased 39.2% and 43.6% 
when treated 0.1 and 0.5 µM Danu, respectively 
(P<0.01, Figure 5). Collectively, these findings indicate 
that Danu induces apoptosis and autophagy via the 
PI3K/Akt/mTOR signaling pathway in Hep3B cells. 
Inhibition of autophagy enhances the 
anticancer effect of Danu in Hep3B cells 
Under most circumstances, autophagy 
represents a pro-survival process against apoptosis; 
but in other special settings, it culminates in 
alternative cell death [47]. So we next used the MTT 
assay to examine the role of autophagy in the 
anticancer effect of Danu in Hep3B cells. Coincubation 
with 40 μM CQ and 0.5 µM Danu markedly decreased 
the viability of Hep3B cells (71.0%), compared to the 
group treated with 0.5 µM Danu (91.4%) or 40 μM CQ 
(82.5%) alone (P<0.001 or 0.05, Figure 6). These 
preliminary data suggest that Danu might trigger a 
cyto-protective autophagy in Hep3B cells.  
Discussion  
Studies have showed that Aurora kinases A and 
B are overexpressed in human HCCs which is 
associated with aggressive tumor characteristics and 
poor prognosis [22, 48, 49]. These findings indicate the 
importance of Aurora kinases as potential targets for 
the treatment of HCC. A series of Aurora kinase 
inhibitors have been tested for HCC treatment in 
preclinical and clinical studies [28, 33-35, 50-52]. In the 
present study, we evaluated the global proteomic 
responses to Danu, including the related molecular 
targets and signaling pathways, in Hep3B cells using 
a SILAC-based quantitative proteomic approach. The 
proteomic study and subsequent validating assays 
revealed that Danu inhibited the proliferation and 
induced cell cycle arrest, apoptosis, and autophagy in 
Hep3B cells, with the involvement of a number of 
function proteins and pathways.  
 
 
Figure 4. Danu treatment induced autophagy. Hep3B cells were treated with Danu at 0.01, 0.1, and 0.5 µM for 24 hr, and then subject to flow cytometric analysis and 
confocal fluorescence microscopic examination. The protein samples were subject to Western blotting assay. (A) Histograms show autophagy of HepG2 cells and bar graphs 
show the percentage of autophagic Hep3B cells. (B) Representative confocal microscopic images show autophagy of Hep3B cells and bar graph shows the fluorescence level. (C) 
Representative blots of LC3-I, LC3-II, beclin 1, and p62 determined by Western blotting assay. β-Actin was used as the internal control. Bar graphs show the relative level of the 
above proteins. Data are the mean ± SD of three independent experiments. *P<0.01, **P<0.001, and ***P<0.001 by one-way ANOVA. 
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Figure 5. Danu regulates the PI3K/Akt/mTOR signaling pathway. Hep3B cells were treated with Danu at 0.01, 0.1, and 0.5 µM for 24 hr, and the protein samples were subject 
to Western blotting assay. Representative blots of phosphorylation level of PI3K, Akt, and mTOR and the total levels of PI3K, Akt, and mTOR, determined by Western blotting 
assay. Bar graphs show the ratio of p-PI3K/PI3K, p-Akt/Akt, and p-mTOR/mTOR in Hep3B cells. β-Actin was used as the internal control. Data are the mean ± SD of three 
independent experiments. *P<0.05, **P<0.001, and ***P<0.001 by one-way ANOVA. 
 
 
Figure 6. Inhibition of autophagy enhanced the anticancer effect of Danu. Hep3B 
cells were incubated with Danu or CQ alone, or coincubated for 24 hr, and then 
subject to the MTT assay. Data are the mean ± SD of three independent experiments. 
*P<0.05, **P<0.001, and ***P<0.001 by one-way ANOVA. 
 
SILAC-based proteomics can quantitatively and 
globally evaluate the proteomic response to a given 
compound and identify its potential targets and 
related signaling pathways in vitro and in vivo [38-41]. 
Our proteomic data demonstrated the molecular 
targets regulated by Danu were involved in a number 
of important cellular functions, with cellular growth 
and proliferation, cell death, and survival being listed 
in the top five. Besides, several signaling pathways 
relevant to these functions have been revealed, such 
as cell cycle regulation, apoptosis signaling, and 
Myc-mediated apoptosis signaling. The functional 
cluster analysis based on the DAVID also depicted 
these regulatory effects of Danu in Hep3B cells. The 
proteomic results suggest that Danu may target these 
signaling molecules to elicit its anticancer effects in 
the treatment of HCC. Notably, we further validated 
the proteomic responses to Danu treatment in Hep3B 
cells.  
Danu inhibits all three members of the Aurora 
kinase family, Aurora A, B, and C [28]. Inhibition of 
Aurora kinases lead to improper mitotic progression, 
including G2/M phase arrest [28]. We examined the 
effect of Danu on the cell cycle distribution and found 
that Danu treatment induced cell cycle arrest at G2/M 
phase in Hep3B cells, which also verified the 
proteomic data. In general, a cell with suppressed 
CDC2/CDK1-cyclin B1 complex activity would tend 
to be arrested in the G2/M phase, whereas a cell with 
elevated CDC2/CDK1-cyclin B1 complex activity 
would be favored to enter mitosis. We have detected 
inhibition of the dephosphorylation of CDC2/CDK1 
at Tyr15, inhibition of the phosphorylation of cyclin 
B1 at Ser133 and increased expression level of total 
CDC2/CDK1, resulting in inactivation of CDC2/ 
CDK1-cyclin B1 complex and consequently the 
inhibition of the cell cycle progression. Our data also 
showed that, the upstream regulator of CDC2/CDK1 
and CDC25C (Ser216) were involved. In aggregate, 
the proteomics and verification data both indicate that 
Danu exerts a marked cell cycle arresting effect via 
regulation of key functional proteins.  
Disruption of mitochondrial function and the 
resultant cytochrome c release initiate apoptosis 
process, with the latter being activated caspase 
cascade, including activation of caspases 9 and 3 [53, 
54]. Our proteomic data demonstrated that Danu 
regulated mitochondrial function and apoptotic cell 
death. In the present study, the flow cytometric and 
Western blotting results have verified the 
pro-apoptotic effect of Danu. The finding also showed 
cytosolic level of cytochrome c was significantly 
increased and caspase cascade was markedly 
activated in response to Danu treatment, which 
contributes to Danu-induced apoptosis of Hep3B 
cells. Pro- and anti-apoptotic members of the Bcl-2 
family are highly involved in apoptosis [53]. 
Anti-apoptotic members of Bcl-2 are suppressed by 
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post-translational modification and/or by increased 
expression of PUMA [55]. The proteomic study also 
showed a number of proteins were involved in the 
regulation of apoptosis. The Western blotting assay 
showed that Danu disrupted the balance between Bax 
and Bcl-2 with involvement of PUMA.  
Autophagy is the major intracellular degradation 
system and plays a critical role in maintaining 
intracellular hemostasis [56-58]. Under most 
circumstances, autophagy emerges as a biological 
process that promotes cell survival [56, 57]. In recent 
years, the distinct role of autophagy in cell growth, 
survival, and death has been demonstrated to be 
context-dependent in cancer cells [59]. Under certain 
circumstances, the pro-survival functions of 
autophagy may be deleterious and lead to cell death 
[59]. Our proteomics and verification data both 
demonstrated that Danu induced autophagy in 
Hep3B cells. The preliminary study showed inhibition 
of autophagy with chloroquine markedly decreased 
the viability of Hep3B cells. These data suggest that 
Danu might trigger a cyto-protective autophagy in 
Hep3B cells and supports potential application of 
autophagic inhibitors for HCC therapy. 
Although apoptosis and autophagy are 
regulated by distinct signaling pathways, they have 
substantial interconnections in determining cell fate 
[60]. In recent years, various signaling pathways have 
been implicated in the up-regulating or 
down-regulating of apoptosis and autophagy, 
respectively. The PI3K/Akt/mTOR signaling is a 
well-known pathway involved in the regulation of 
both apoptosis and autophagy and may contribute to 
simultaneous or sequential induction of both 
processes [47]. Our proteomic study revealed that 
PI3K/Akt/mTOR signaling pathway was regulated 
by Danu. Subsequent data demonstrated the Danu 
inhibited the phosphorylation of PI3K, Akt, and 
mTOR. We deduce that PI3K/Akt/mTOR signaling 
pathway might be involved in regulating apoptosis 
and autophagy in Hep3B cells, although further 
studies are mandatory. Apart from the signaling 
pathways, the dual regulatory roles of some key 
interconnected molecules in these two pathways have 
been identified, such as Bcl-2 family members, beclin 
1, caspases, and p53 [47, 61, 62]. In the present study, 
the expression of Bcl-2, Bcl-xl, and beclin 1 was 
regulated by Danu; but their roles in the crosstalk 
between apoptosis and autophagy remain to be 
clarified in future studies.  
In conclusion, this SILAC proteomic study 
shows that Danu regulates a number of functional 
proteins and molecular signaling pathways, Danu 
inhibits cell proliferation, induces cell cycle arrest, 
apoptosis, and cyto-protective autophagy. Inhibition 
of autophagy increases the sensitivity of Hep3B cells 
to Danu. More functional and mechanistic studies are 
needed to elucidate the role of Danu in the treatment 
of HCC. 
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